Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Recombination Activating Gene 2 (RAG2) Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAG2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAG2 Recombinant Protein (Full Length / PHD Domain) High purity (>90% by SDS-PAGE), Sequence Verified, Endotoxin Controlled. Suitable for binding assays. |
View RAG2 Products |
| Gene Delivery | RAG2 Promise-ORF / Lentivirus Full-length human RAG2 ORF for stable overexpression in cell-based recombination assays. |
View RAG2 Products |
| Benchmark Ab | Anti-RAG2 Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and intracellular flow cytometry. |
View RAG2 Products |
| Validator | RAG2 siRNA Set Target-specific knockdown pool for functional validation of RAG2-dependent V(D)J cleavage. |
View RAG2 Products |
| Related Target A | RAG1 Essential catalytic partner of RAG2; forms the active heterotetramer complex required for DNA cleavage. |
View RAG1 Products |
| Related Target B | PRKDC (DNA-PKcs) Key downstream kinase in the non-homologous end joining (NHEJ) pathway that repairs RAG-induced double-strand breaks. |
View PRKDC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the active RAG1/2 complex | Co-expression compatible RAG1 and RAG2 constructs with verified sequence identity and high purity. |
| PHD finger-chromatin interaction screening | Highly purified RAG2 C-terminal PHD finger domain expressed in native folding systems. |
| Lack of reliable positive controls | Sequence-defined recombinant antibodies targeting specific RAG2 epitopes. |
| Off-target assay validation | Validated siRNA sets to confirm target specificity in gene-editing and small-molecule studies. |
Live RAG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RAG2 is expanding beyond its classical association with Severe Combined Immunodeficiency (SCID). While gene therapies and gene-editing strategies aim to restore RAG2 function in patients with immune deficiencies, emerging oncology research focuses on RAG2 inhibition. Aberrant RAG2 expression or activity is implicated in genomic instability, chromosomal translocations, and the progression of certain lymphoid malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL). Consequently, the next wave of R&D is targeting the protein-protein interaction (PPI) between RAG1 and RAG2, as well as the interaction of the RAG2 PHD finger with methylated histone H3K4me3.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | T-ALL, B-cell Lymphomas, Autoimmune Diseases | Interaction Screening (Need purified RAG1/RAG2 complexes and H3K4me3 binding assays) |
| Gene Therapy (Lentiviral/AAV) | Clinical Stage Gene Therapy Developers | RAG2-deficient SCID | Expression Validation (Need sequence-verified RAG2 antibodies and ORF vectors) |
| Gene Editing (CRISPR/Cas9) | Academic & Clinical Consortiums | SCID, Primary Immunodeficiencies | Functional Knockout Verification (Need validated RAG2 siRNA and target-specific primers) |